
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded topical gel containing alprostadil, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing alprostadil are listed in injection form. No finished alprostadil product of any kind is listed in gel form.
Gel bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Alprostadil is a synthetic prostaglandin E1 vasodilator that compounding pharmacies prepare as sterile intracavernosal injections and urethral preparations by prescription.
Alprostadil is a man-made version of prostaglandin E1, a natural signaling molecule. Injected into the side of the penis, it raises cyclic AMP inside the smooth muscle of the erectile tissue, relaxing that muscle and widening the cavernosal arteries so blood flows in and is trapped, producing an erection without sexual stimulation. Manufactured products are Caverject and Caverject Impulse (Pfizer) and Edex (Endo), powders for intracavernosal injection, FDA-approved for erectile dysfunction; Caverject is also approved as an adjunct to other diagnostic tests for erectile dysfunction. Muse, a urethral suppository approved in 1996, is listed by FDA as discontinued. A prescriber might order compounded alprostadil as a ready-to-use sterile solution, in a strength or volume not manufactured, in a urethral form, or combined with papaverine and phentolamine in a single injection. Compounded preparations are not FDA-approved and require a prescription.
Caverject and Edex carry no boxed warning, but both labels warn about priapism. The Caverject label says an erection lasting more than four hours needs medical care right away (the Edex label says six hours) to prevent permanent damage. Penile scarring or curvature developed in about 3 percent, and penile pain was the most common side effect. Do not use alprostadil if you have sickle cell disease or trait, multiple myeloma, leukemia, Peyronie's disease or another penile deformity, or a penile implant. Alprostadil also generally should not be used by men who have been told sexual activity is unsafe for them. Blood thinners raise bleeding and bruising at the injection site, and combining alprostadil with other injected erection drugs adds to the risk of prolonged erection, priapism and low blood pressure. The first dose is given in the prescriber's office; follow injection training exactly, since needles have broken off. It does not protect against sexually transmitted infections and is not for use in females. If side effects bother you, talk to your prescriber or pharmacist.
Alprostadil (PGE1) raises intracellular cAMP in trabecular smooth muscle and cavernosal arteries, producing relaxation and a corporal veno-occlusive effect; it also inhibits platelet aggregation. After intracavernosal injection, peripheral plasma levels do not rise significantly above endogenous baseline; about 80 percent of circulating drug is cleared in a single pulmonary pass by beta- and omega-oxidation, the principal metabolite peaks at 30 minutes and returns to baseline by 60 minutes, and excretion is renal. Protein binding is about 81 percent to albumin. Labeled indications: Caverject and Caverject Impulse for erectile dysfunction and as an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction; Edex for erectile dysfunction of neurogenic, vasculogenic, psychogenic or mixed etiology. Prescribers have ordered compounded alprostadil in intracavernosal mixtures with papaverine and an alpha-blocker, a practice reviewed by Bobo et al. (Expert Opin Pharmacother 2023;24(8):925-933), whose authors stress patient selection and counseling; the Caverject label notes that combination intracavernosal use has not been studied for safety and may increase risk. The AUA guideline advises an in-office injection test before home therapy. Dosing and titration are per prescriber. Monitor for prolonged erection, cavernosal fibrosis or angulation on examination, injection-site hematoma, and symptomatic hypotension, especially with venous leakage. Not a controlled substance.
Wash your hands. Apply the amount on your label to clean, dry skin and spread it in a thin layer. For a metered pump, your label states the number of presses. For a dosing syringe, push the plunger to the mark. Let the gel dry before covering with clothing. Wash your hands afterward and keep the site from touching other people until it has dried. Do not apply to broken skin unless told to.
A gel can have a nonaqueous or a water-based base, and USP <795> sets its default beyond-use date by water content, not by the word gel. A nonaqueous gel usually carries a beyond-use date of up to 180 days at room temperature or refrigerated. A water-based gel carries up to 35 days with a preservative, or 14 days refrigerated without one. Your label states which applies. Keep the container closed, away from heat and open flame if it contains alcohol, out of reach of children, and discard after the beyond-use date on your label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)